Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,452

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Deep Vein Thrombosis
Interventions
DRUG

SanOrg34006

DRUG

LMW heparin

DRUG

Unfractionated heparin

DRUG

Vitamin K antagonist (VKA)

Trial Locations (24)

11030

North Shore University Hospital, Manhasset

14642

University of Rochester Medical Center, Rochester

18103

Lehigh Valley Hospital, Allentown

22304

Inova Alexandria Hospital, Alexandria

22401

Pulmonary Associates, Fredericksburg

23249

McGuire VAMC, Richmond

30912

Medical College of Georgia, Augusta

32216

Jackson Cardio-Vascular Clinic, Jacksonville

32901

MIMA Century Research Associates, Melbourne

48341

St. Joseph Mercy - Oakland Research Center, Pontiac

58201

Health System Research Center, Grand Forks

60201

Evanston Northwestern Healthcare, Evanston

60513

Loyola University of Chicago, Maywood

60611

Northwestern University, Chicago

66061

Consultants in Pulmonary Medicine, Olathe

73104

University of Oklahoma HSC, Oklahoma City

76508

Scott and White Memorial Hospital & Clinic, Temple

77030

James Muntz, Houston

80129

University of Colorado Health Sciences Center, Denver

87108

Lovelace Health Systems, Albuquerque

98122

Swedish Medical Center, Seattle

99203

William Dittman, Spokane

30033-6136

DeKalb Medical Center, Decatur

02118

Boston Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY